ERCC2 and colorectal carcinoma: Park et al [6] found that advanced-stage CRC patients with XPD Gln/Gln genotype treated with chemotherapy tended to have progressive disease and significantly reduced survival, compared to patients with XPD Lys allelic variants (P = 0.002).